Hughes Stovin: Sustained remission and regression of pulmonary aneurysms with anti–tumor necrosis factor treatment

Research output: Contribution to journalArticlepeer-review

Abstract

We report the first case of Hughes Stovin Syndrome successfully treated with long-lasting tumor necrosis factor α (TNF-α) blocker (infliximab) treatment. Because of the failure of the standard therapeutic regimen with steroids and cyclophosphamide, infliximab was started achieving a stable disease remission and a complete resolution of pulmonary aneurysms. Hughes Stovin Syndrome, although rare, is a life-threatening condition that needs to be timely identified and treated aggressively. Our report underlines the importance of TNF-α blocker treatment in Hughes Stovin Syndrome, suggesting its use as long-term safe and useful.

Original languageEnglish
Pages (from-to)E13-E15
JournalPediatric Pulmonology
Volume54
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • antiTNF-α
  • Hughes Stovin
  • pulmonary aneurisms
  • treat ment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Hughes Stovin: Sustained remission and regression of pulmonary aneurysms with anti–tumor necrosis factor treatment'. Together they form a unique fingerprint.

Cite this